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Fatimah Al-Fadhly3, Riham El Sayed4, Roslyn J Simms1, Brian Meyer2 and John A Sayer1*Abstract
Background: Bardet-Biedl syndrome (BBS) is an autosomal recessive ciliopathy disorder with 18 known causative
genes (BBS1-18). The primary clinical features are renal abnormalities, rod-cone dystrophy, post-axial polydactyly,
learning difficulties, obesity and male hypogonadism.
Results: We describe the clinical phenotype in three Saudi siblings in whom we have identified a novel mutation
in exon 12 of BBS5 (c.966dupT; p.Ala323CysfsX57). This single nucleotide duplication creates a frame shift results in a
predicted elongated peptide. Translation blocking Morpholino oligonucleotides were used to create zebrafish bbs5
morphants. Morphants displayed retinal layering defects, abnormal cardiac looping and dilated, cystic pronephric
ducts with reduced cilia expression. Morphants also displayed significantly reduced dextran clearance via the
pronephros compared to wildtype embryos, suggesting reduced renal function in morphants. The eye, kidney and
heart defects reported in morphant zebrafish resemble the human phenotype of BBS5 mutations. The pathogenicity
of the novel BBS5 mutation was determined. Mutant mRNA was unable to rescue pleiotropic phenotypes of bbs5
morphant zebrafish and in cell culture we demonstrate a mislocalisation of mutant BBS5 protein which fails to
localise discretely with the basal body.
Conclusions: We conclude that this novel BBS5 mutation has a deleterious function that accounts for the
multisystem ciliopathy phenotype seen in affected human patients.
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BBS is a rare autosomal recessive disorder [1] which is
now considered, given its pleiotropic and multisystem
features and the known function of BBS proteins, to be a
ciliopathy. The incidence of BBS, has been reported to be
1 in 125,000 in the UK [1] and 1 in 160,000 in Switzerland
[2]. It is more common in some small populations such as
Newfoundland (1 in 18,000) [3] and the Bedouin commu-
nity of Kuwait (1 in 13,500) [4] where there may be a
founder effect [5] and an increased incidence of consan-
guineous relationships [6].
Following a comprehensive analysis of known BBS pa-
tients in the UK, Beales et al. provided revised diagnostic
criteria for the clinical syndrome. Currently, four out of
six primary features of BBS or three out of six primary
features and at least two of eleven secondary features are
required for a clinical diagnosis [7] The primary features* Correspondence: john.sayer@ncl.ac.uk
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2014include renal abnormalities (renal cystic dysplasia and
anatomical malformations), rod-cone dystrophy, post-
axial polydactyly, learning difficulties, truncal obesity
and male hypogonadism [7]. The renal manifestations of
BBS are the most life-limiting component of the disorder
[8,9]. Out of the 11 secondary features, four (brachy-
dactyly, developmental delay, speech deficit and high-
arched palate) have been reported to affect over 40% of
BBS patients [7]. There is considerable variation in the
phenotypes of affected individuals, even between affected
siblings [10]. Additional phenotypes have also been re-
ported in BBS patients, including cardiac malformations
[11], situs inversus [12] and anosmia [13].
BBS is a genetically heterogeneous disorder with muta-
tions in 18 known genes (BBS1-18) [14-16] accounting for
approximately 80% of patients with BBS. In 2004, Li et al.
identified BBS5 using an elegant comparative genomics
method [17]. Comprehensive bioinformatics carried out on
BBS5 by Nachury et al. discovered that two novel domains
in the BBS5 protein were similar to pleckstrin homology
(PH) domains which bind to phosphoinositides [18].ral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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phatidylinositol that are found in cell membranes and have
functional links with RABs including Rab8 [19]. BBS5 iso-
lates bind to phosphoinositides in vitro and because both
siRNA inhibition of BBS5 and inhibition of phosphoinosi-
tides resulted in loss of ciliation [18], this suggests that BBS5
binding to phosphoinositides is needed for ciliogenesis [18].
We report an interesting novel BBS5mutation in a consan-
guineous family from Saudi Arabia. Given that this mutation
was not a missense or nonsense mutation but led to a pre-
dicted elongated transcript that may retain functional activity,
we sought to characterise this mutation further. The patho-
genicity of this novel mutation was assessed in a zebrafish
model, where it was unable to rescue pleiotropic pheno-
types of bbs5 knockdown and in cell culture assays, where
the novel mutation led to BBS5 mutant protein mislocali-
sation in renal epithelial cells (Qiagen, Manchester, UK).
Methods
Study cohort
This study has been approved by the research advisory
council of King Faisal Specialist Hospital, Riyadh, Saudi
Arabia (RAC#2050 045). Following informed consent,
DNA was extracted from peripheral blood cells using
the Gentra Systems Puregene DNA Isolation kit (Qiagen,
Manchester, UK).
Homozygosity mapping and mutation analysis
To search for homozygous regions and possible chromo-
somal abnormalities, all available family members were
genotyped with an Affymetrix® CytoScan™ Array. The pri-
mary data was analysed using Chromosome Analysis Suite
(ChAS) software (Affymetrix). Direct sequencing of all co-
ding exons and exon-intron boundaries of BBS5 was per-
formed. Primer sequences are available upon request. PCR
products were sequenced using BigDye™ Terminator Cycle
Sequencing kit (PE Applied Biosystems, Bedford, MA,
USA). Sequences were analysed using Mutation Surveyor®
software Version 3.24 (SoftGenetics LLC, State College, PA
16803, USA). Mutations were labelled according to the
Human Genome Variation Society (HGVS) recommenda-
tions version 2.0. A control DNA panel from 96 individuals
from a Saudi Arabian population was used to screen for the
novel sequence variant.
Zebrafish studies
For zebrafish studies, all procedures were performed
under Home Office UK license regulations. Transgenic
fluorescent reporter fish were used for studying cardiac
morphology (cmlc2:GFP, the GFP gene under the control
of the cardiac myosin light chain 2 gene promoter [20])
and renal morphology (cldnb:lynGFP, a membrane-
localised variant of the GFP gene under the control of
the claudin b gene promoter [21]). Other zebrafish linesused were wildtype (WT) AB and golden. Zygotes were
collected from natural spawning and placed in petri dishes
of E3 medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM
CaCl2, 0.33 mMMgSO4) [22].
Morpholino oliogonucleotides (MOs) were manufactured
by Gene Tools LLC (Philomath, OR, USA). The standard
control (5′-CCTCTTACCTCAGTTACAATTTATA-3′)
and p53 translation targeting (5′-GCGCCATTGCTTTG
CAAGAATTG-3′) MO sequences were of pre-established
design. MO sequences for bbs5 translation targeting
(ATG) (5′-GATCACTGTCTGCGTATATTGTCGA-3′)
were designed with reference to the zebrafish genome
assembly Zv9.
Stock MOs in RNase free water were diluted with
0.05% phenol red in Danieau buffer to produce the solu-
tion for injection. Dilutions of 3 to 12 ng of MO per 2 nl
of solution were used. All MOs, except the p53 ATG
MO, were used individually. The p53 ATG MO was co-
injected in a 1:1 mixture with the bbs5 ATG MO in
order to assess any p53-mediated off-target effects [23]
of the bbs5 ATG MO. MOs were microinjected under
light microscopy into the yolk of one- to four-cell em-
bryos, using a glass micropipette and an Eppendorf Fem-
toJet pneumatic micro-injector. The micropipettes were
calibrated by measuring droplet size on a reticle so that
2 nl of MO solution were injected into each embryo.
After microinjection, the embryos were placed in fresh
E3 medium, approximately 50 embryos per petri dish,
and incubated at 28.5°C. Mortality counts were per-
formed at 3 and 24 hours post fertilisation (hpf ) on both
injected and uninjected control embryos. Clutches where
the mortality rate in uninjected embryos was above 50%
at 24 hpf were discarded.
Human BBS5 EST clone (BC044593.1) inserted into
vector pBluescriptR was obtained (GeneService) and the
clone was sequenced to verify clone length and fidelity.
To obtain mutant BBS5 (c.966dupT), site directed muta-
genesis was employed. Using a T7 forward oligonucleotide
primer and reverse oligonucleotide primer within the 3′
UTR of BBS5, PCR products of 1,194 bp were obtained
and used as a template to perform an in vitro synthesis of
large cRNA (mMessage mMachine T7 kit (Ambion, Inc.,
AM1340)). cRNA samples were purified by phenol:chloro-
form extraction and isopropanol precipitation.
cRNA was mixed 1:1 with bbs5 ATG MO in its micro-
injection solution to achieve 100 pg of mRNA and 5 ng
of MO in 2 nl of the final solution. This solution was
then microinjected into one- to four-cell embryos as de-
scribed. Western blotting was used to confirm WT
BBS5-NT-GFP and c.966dupT mutant BBS5-NT-GFP
protein expression. Briefly, protein was extracted using
an extraction buffer (4 M urea, 125 mM Tris pH 6.8,
4% SDS, 10% glycerol, 5% beta-mercaptoethanol, and
0.02% bromophenol blue). Samples were separated using
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phoretically transferred to Hybond-C-extra nitrocellulose
membranes (Fisher Scientific UK Ltd). Protein was de-
tected using an anti GFP-HRP (Santa Cruz sc-9996, Santa
Cruz Biotechnologies Inc., Santa Cruz, CA, USA) (1 in
5,000 dilution) for one hour at room temperature before
developing and imaging.
Zebrafish phenotypic data
Light and fluorescent microscopy was performed to
monitor the embryos at 24, 48 and 72 hpf. Embryos
were dechorinated (using forceps) and immobilised in
0.1% tricaine in E3. The phenotypes of each fish at 72
hpf were recorded, noting the presence of pericardial ef-
fusion, tail length and appearance, body oedema and
venous stasis in the cardiac venous sinus. Pronephric
duct morphology assessment in cldnb:lynGFP fish was
performed at 48 hpf and 72 hpf. For ciliary staining, em-
bryos were fixed in acetone and stained with mouse
acetylated tubulin antibody (Sigma, UK), secondarily de-
tected with Alexa Fluor 594 (Invitrogen Life Sciences
Ltd.). To assess cardiac morphology (D-loop, L-loop or
failure of looping and cardiac chamber appearance), 72
hpf cmlc2:GFP embryos were used.
Fish were classed phenotypically as i) normal if they
were indistinguishable from uninjected fish; ii) mildly af-
fected if they had small eyes, mild pericardial effusion and
mild/no tail defects; iii) moderately affected if they had a
large pericardial effusion and moderate tail defects (obvi-
ous shortening and large kinks/curls in their tails). Fish
exhibiting a very severe or ‘monster phenotype’ [24] (no or
very short malformed tail, widespread oedema, malformed
eyes and minimal cardiac muscle contraction) were noted
but not used in the analysis of morphology [24]. Eye size
was measured using superior view photograph using the
long axis length of each zebrafish eye. Images were taken
with a Leica DF425C camera and the Leica Application
Suite V3 program and analysis was performed using
ImageJ Software (National Institutes of Health).
Histological analysis of zebrafish morphants
Seventy-two hpf control and bbs5 ATG MO injected
(mild to moderate phenotype) embryos were euthanised
in 4% tricaine and fixed in 2% glutaraldehyde in 0.1 M
cacodylate buffer for two hours at room temperature.
They were then dehydrated in a stepwise manner in
acetone then impregnated with epoxy resin in stepwise
fashion. Embryos in 100% epoxy resin were then placed
individually in coffin moulds (EMS #70905-01) and poly-
merised at 60°C for 24 hours. One micrometer trans-
verse microtome sections were stained with 1% toluidine
blue in 1% borax. In parallel, zebrafish were also embed-
ded in (Electron Microscopy Sciences, Hatfield, PA,
USA) and allowed to set in a low humidity environment.A glass knife was used to cut 5 μm sections which were
then stained by Lee’s trichrome and mounted in Hista-
mount. Sections were then analysed on a Zeiss Axioplan
2 light microscope and images were taken (Zeiss Axio-
Cam HRc camera).
Renal function studies in zebrafish embryos and
morphants
Uninjected control embryos and bbs5 ATG MO injected
embryos with a mild to moderate phenotype were selected
at 48 hpf and dechorinated and immobilised using 0.1%
tricaine in E3. Four nanograms of 10 kDa tetramethylrhoda-
mine dextran (dissolved in RNase free water) were micro-
injected into the cardiac venous sinus, lateral and inferior to
the heart. To confirm successful cardiac injection, embryos
were checked for the presence of fluorescence within the
heart under fluorescent microscopy. A lateral view fluores-
cent image of each fish was taken at 3, 24 and 48 hours post
dextran injection keeping exposure, saturation, gamma, gain
and zoom level were all constant. A 100 × 100 pixel square
from the centre of the heart for each fish was taken and the
average intensity measured using ImageJ software. Prone-
phric ducts and cilia were visualised using a Nikon A1R con-
focal microscope and Elements software package.
Cell culture and transfection
Routine tissue culture techniques were used to facilitate
the growth of the Human Embryonic Kidney 293 cells
(HEK293) mammalian cell line [25]. Cell lines were cul-
tured in DMEM. Human BBS5 (EST clone reference
5272889) and mutant BBS5 (c.966dupT) and WT plas-
mids were subcloned into pcDNA3.1-NT-GFP vector
(Invitrogen Life Technologies Ltd, UK). Following subclon-
ing into pcDNA3.1-NT-GFP, clones were fully sequenced
to confirm sequence fidelity, reading frame and orientation
(data not shown). Following successful cloning, large scale
preparations of plasmid cDNA were obtained using over-
night culture in Luria Broth and isolation and isolation of
DNA using a MaxiPrep kit (Qiagen, Manchester, UK).
For transfection, Lipofectamine 2000 reagent (Life Tech-
nologies, UK) was used empirically as per the manufac-
turer’s protocol. Cells were fixed 24 to 48 hours post
transfection in 4% paraformaldehyde (PFA) and permeabi-
lised using 0.5% Triton-X100 (Sigma, UK) in PBS solution.
Cell immunofluorescence staining
Following blocking with 5% BSA, cells were labelled with
mouse acetylated tubulin (1:1,000; Sigma, UK) and detected
using Alexa Fluor 594 donkey anti-mouse (1:200; Invitrogen
Life Technologies Ltd, UK). Labelling with pericentrin anti-
body (1:200; Abcam, Cambridge, UK) was secondarily de-
tected using an anti-rabbit Cy3 antibody (1:200, Invitrogen
Life Technologies Ltd, UK). Cells were imaged using
confocal laser scanning microscopy, (Nikon U.K. Ltd).
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Zebrafish phenotype data was analysed using chi-squared
test. Eye size and cardiac fluorescence intensity were com-
pared using an unpaired two-sample t-test (MiniTab 16
software, Minitab Ltd., Coventry, UK).
Results
Molecular genetic diagnosis
We performed homozygosity mapping using SNP markers
on all three affected patients and both parents of a SaudiFigure 1 Family structure and molecular genetic diagnosis of a novel
(shaded figures) from a consanguineous family with BBS. Circles represent
shown by a dotted symbol. (B) Sequencing chromatogram s from exon 12
affected son (IV:4) and segregation of the mutation from each parent.Arabian family (Figure 1A) where a clinical diagnosis of
BBS was suspected in three of their children (Table 1). All
three affected children met the current diagnostic criteria
for BBS, each having 4/6 primary and 2/11 secondary BBS
features.
A region of homozygosity on chromosome 2 (chr2:170,
310,006-170,383,165) shared by all three affected children
was identified (data not shown) which included two genes:
a known BBS gene, BBS5 and KBTBD10. The BBS5 gene
contains 12 exons, all of which are coding and its full-BBS5 mutation. (A) Pedigree diagram showing three affected siblings
females, squares represent males. Carrier (heterozygous) status is
of BBS5 gene showing a homozygous duplication of T nucleotide in
Table 1 Clinical features of three affected siblings
Primary BBS features Secondary BBS features
Age at presentation
(years)
Post axial
polydactyly
Retinal
dystrophy
Renal
anomalies
Learning
difficulties
Hypogonadism Obesity Developmental
delay
Congenital
heart disease
Astigmatism
Affected female 9 Y Ya Yb Y n/a Y Y N Y
Affected female 7 Y N Yc Y n/a Y Y VSD N
Affected male 3 Y N N Y Y Y Y VSD N
anight blindness and retinal dystrophy developed at aged 12.
bdilatation of left renal pelvis.
cbilateral small kidneys on USS. VSD, ventricular septal defect.
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Direct sequencing of all 12 coding exons of BBS5 was per-
formed and a novel homozygous frameshift mutation
c.966dupT (p.Ala323CysfsX57) in exon 12 of BBS5 was
identified in all three affected individuals, with the muta-
tion segregating from both parents (Figure 1B). The un-
affected son was heterozygous for the mutation. The
mutation affects a highly conserved region of the BBS5
protein and results in a predicted elongated peptide that
has 379 amino acids instead of 341 in the WT. The muta-
tion was not found in 100 DNA normal controls from a
Saudi Arabian population.
In vivo modelling of novel BBS5 mutation in zebrafish
Since our main goal was to demonstrate that the
c.966dupT BBS5 mutation is pathogenic, we wanted to
assess whether the mutated BBS5 retains full function.
One way of testing this is to perform in vivo rescue experi-
ments and the zebrafish is a good model to use for this for
a number of reasons. The zebrafish can be used to assess
the pleiotropic phenotype typical of BBS, and has been
used successfully to characterise phenotypes of bbs1, bbs2,
bbs4, bbs5, bbs6, bbs7 and bbs8 [26,27]. The zebrafish
model has also been successfully utilised to examine the
effect of pair-wise BBS gene knockdown in order to study
genetic interactions [27]. In addition, morphant zebrafish
can be used in co-injection experiments to determine the
degree of rescue of WTand mutated mRNAs.
Using zebrafish embryos, MOs were designed and in-
jected to modify gene expression of BBS5. Delivered doses
of 4 ng, 6 ng, 8 ng and 12 ng of bbs5 ATG MO each pro-
duced a range of phenotypes at 72 hpf including normal,
mild, moderate and severe (Figure 2). Mild phenotypes in-
cluded pericardial oedema and mild eye and tail defects.
Moderate and severe phenotypes included curly tails,
small eyes and prominent cardiac and pericardial oedema.
There was a dose–response progression in phenotype
from mild to more severe as doses increased, consistent
with specificity of the bbs5 ATG MO (Figure 2E). Using a
4 ng dose, 22% of embryos displayed any phenotype,
whilst a 12 ng dose produced a mild phenotype in 25%, a
moderate phenotype in 25% and a severe phenotype in
36% of embryos. A dose of 6 ng bbs5 ATG MO was used
for subsequent phenotyping experiments. To exclude off-
target effects of bbs5 MO injection, embryos were co-
injected with 6 ng of both p53 and bbs5 ATG MOs (n =
144) or 6 ng bbs5 ATG MO alone (n = 143). There was no
detected difference in phenotype between the two groups
and they both had similar distributions of phenotypic se-
verity (data not shown).
Retinal phenotype
Given that the 72 hpf phenotype of morphants under
light microscopy included microphthalmia (Figure 3B),we attempted to quantify this further. The mean eye diam-
eter of bbs5 ATG morphant fish with a mild to moderate
phenotype was significantly smaller (243 pixels (n = 30))
compared to control fish (328 pixels (n = 28), P < 0.001).
Histological examination of WT embryo retina at 72 hpf
displayed normal retinal layering, with each layer appearing
intact and distinct (Figure 3C). In bbs5 morphants, retinal
sections demonstrated a microphthalmia with partial loss
of the retinal layering. The photoreceptor layer was dis-
rupted when compared to WT, and the lens and retina
seemed to have separated from each other in the mor-
phant embryos (Figure 3D).
Cardiac phenotype
At 48 hpf bbs5 ATG MO injected morphant embryos
displayed abnormal hearts (Figure 4B-D). In 98% of WT
embryos (n = 173), the hearts had a single atrium and
ventricle that had undergone D-looping, resulting in the
atrium being on the left side of the embryo and the ven-
tricle on the right (Figure 4A). Morphant embryos (n =
218) demonstrated L-looping in 12%, resulting in the
atrium being on the right side of the embryo and the
ventricle on the left. A larger proportion of morphant
hearts failed to loop (27%), resulting in both the atrium
and the ventricle remaining in the medial position
(Figure 4E).
Renal phenotype
Pronephric duct morphology was analysed in cldnb:
lynGFP embryos, which have a fluorescent pronephric
duct (Figure 5A-D and Additional file 1: Figure S1). Exam-
ination of pronephric ducts under light microscopy is very
subjective but examining embryos with fluorescent pro-
nephric ducts allowed accurate phenotyping to be per-
formed in living fish (Additional file 1: Figure S1). Dilated
pronephric ducts were observed in 2% of WT embryos
(n = 84), compared to 29% of morphant embryos (n = 79).
In addition, 23% of morphant embryos displayed proneph-
ric or cloacal cysts. No cysts were observed in WT em-
bryos (Figure 5E). Using WT mRNA we were able to
rescue the cystic phenotype. In addition, we utilised zebra-
fish embryos to determine evidence of kidney dysfunction,
using methodology initially developed by Hentschel et al.
[28]. Embryonic renal clearance in morphant zebrafish
may be assessed by microinjection then subsequent track-
ing the elimination of a fluorescently-tagged dextran
through serial image capture [29]. To estimate renal func-
tion bbs5 morphants (n = 16) and WT (n = 17) embryos
were followed over a 48-hour period after cardiac venous
sinus fluorescent dextran injection. Two morphant em-
bryos and one WT embryo died before the end of the
observation period and were excluded from the analysis.
At 24 hours post dextran injection, morphant embryos
retained significantly more fluorescence than WT embryos.
Figure 2 (See legend on next page.)
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Figure 2 Phenotypic spectrum following bbs5 ATG MO injection and mRNA rescue. At 72 hpf following bbs5 MO injected (+/- mRNA
rescue) zebrafish were phenotyped under light microscopy. Representative images are shown: (A) wildtype (WT) phenotype; (B) mildly affected
morphant, showing a pericardial effusion and small eyes; (C) moderately affected morphant with a pericardial effusion, small eyes and a curly tail
and (D) a severely affected morphant with a large pericardial effusion, small eyes and severe tail curvature. (E) Dose–response analysis of
phenotypes following bbs5 ATG MO injection. Fish were classed phenotypically as normal if they were indistinguishable from uninjected fish;
mildly affected if they had small eyes, mild pericardial effusion and mild/no tail defects; moderately affected if they had a large pericardial
effusion and moderate tail defects, and severe if there was absent or very short malformed tail, widespread oedema, malformed eyes and
minimal cardiac muscle contraction). Note a trend of increasing severity of phenotypes from 4 ng to 12 ng MO dose. The number of embryos (n)
injected for each dose are shown. (F) Phenotypes of bbs5 ATG MO injected fish compared to co-injected WT BBS5 mRNA and mutant (Mut)
BBS5 mRNA.
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fluorescence ratio was 0.630 for morphants, compared to
0.417 for WT embryos (P = 0.005). At 48 hours post dex-
tran injection the 48-hour to 3-hour fluorescence ratio
was 0.278 for morphants and 0.112 for WT (P = 0.002)
(Figure 5F). This data is consistent with a reduction in
renal excretory function in bbs5 morphants. Fluorescent
confocal microscopy confirmed pronephric duct dilatation
in bbs5 morphant embryos at 72 hpf. Interestingly, the
pronephric cilia of bbs5 morphants were less dense and
had an irregular pattern in appearance (Figure 5G).
In order to study the pathogenic effects of novel human
BBS5 mutation identified in our Saudi Arabian family, we
used mutant mRNA for co-injection studies to determineFigure 3 Microphthalmia and retinal layering defect in bbs5 morphan
microscopy of 72 hpf embryos show a reduction in eye size in between (A
demonstrating (C) WT retina with normal, well demarcated retinal layering
layering, loss of photoreceptor layer and separation of lens from retina (*).
co-injected with bbs5 MO. (E) Retinal layers are preserved in WT and (F) di
phenotype and eye size whilst in the (H) mutant mRNA phenotype retinal
ganglion cell layer; INL, inner nuclear layer; IPL, inner plexiform layer; PL, phits ability to rescue the morphant phenotype (Figure 2F).
Injection of 4 ng bbs5 ATG MO alone showed phenotypes
in 18% of fish (n = 194) whilst co-injection of bbs5 ATG
MO with WT BBS5 mRNA in an attempt to rescue the
phenotype, showed only a mild (cardiac/renal/tail) pheno-
type in approximately 6% of fish (n = 103). Zebrafish dem-
onstrating complete rescue and partial rescue of the
dilated pronephros, cystic pronephros and tail phenotypes
using WT BBS5 mRNA are shown in Additional file 1:
Figure S1. Just 3% of zebrafish co-injected with bbs5 ATG
MO and WT BBS5 demonstrated a dilated pronephros.
In these rescue experiments, there was an absence of
moderate and severe phenotypes including situs inver-
sus and severe tail curvature. Co-injection of bbs5 ATGts and phenotypic rescue with mRNA co-injection. Light
) wildtype (WT) and (B) bbs5 morphants. Retinal sections
compared to (D) morphant retina displaying partial loss of retinal
In mRNA rescue experiments, WT mRNA or mutant mRNA was
srupted in bbs5 morphants. (G) WT mRNA is able to rescue the retinal
layers remain disrupted and the eye size small. Scale bar 100 um. GCL,
otoreceptor layer, RPE, retinal pigment epithelia.
Figure 4 bbs5 morphants display cardiac anomalies including situs inversus. Wildtype (WT) and morphant cmlc2:GFP embryos were imaged
at 48 hpf. (A) WT heart showing normal looping (D-looping) with the atrium (a) on the left hand side of the embryo and the ventricle (v) on the
right. (B) Morphant heart with preserved D-looping. (C) Morphant heart with looping in the opposite direction (L-looping) resulting in the atrium
on the right of the embryo and the ventricle on the left. (D) Morphant heart, which shows a failure of looping, resulting in a heart with neither
the atrium nor ventricle leaving the midline. (E) 98% of WT embryos displayed D-looping whilst just 61% of morphant embryos exhibited
D-looping, 12% exhibited L-looping, and 27% of morphant hearts were unlooped (P < 0.001).
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(cardiac/renal/tail) phenotype in 25% of fish embryos
(n = 78), including 9% severe and 7% with moderate phe-
notypes (Figure 2F). These experiments point to the direct
pathogenicity of the c.966dupT mutation. Furthermore,
histological examination of retina from morphant em-
bryos co-injected with WT mRNA showed a recovery of
the retinal layering phenotype (Figure 3G) and correction
of eye size (Figure 3G). In contrast, co-injection with mu-
tant mRNA failed to rescue the phenotype with disruption
of retinal layering remaining (Figure 3H). Western blot-
ting at 48 hours was used to confirm expression of theWT and c.966dupT mutated BBS5-NT-GFP proteins
(Additional file 2: Figure S2).
Localisation of wildtype and mutant BBS5-NT-GFP in
HEK293 cells
WT and mutant BBS5-NT-GFP were transfected into
HEK293 cells to assess the pathogenicity of the mutation
detected (c.966dupT) at the cellular level. BBS proteins
typically localize to the basal body of ciliated cells [30].
A basal body localization of WT BBS5-NT-GFP protein
in HEK293 was demonstrated with colocalisation of BBS5-
NT-GFP and pericentrin (Figure 6A,B). Transfection of the
Figure 5 Characterisation of pronephros structure and function in bbs5 morphants. (A-D) Superior and lateral views of a cldnb:lynGFP
embryo displaying (A,B) normal pronephric ducts (arrowed) and cloaca (*) in wildtype (WT) zebrafish. (C,D) bbs5 morphant embryos displayed
dilated and tortuous pronephric ducts (identified by GFP fluorescence) and a (D) cloacal cystic dilatation. Scale bars are 100 μm. (E) Quantification
of pronephros abnormalities in WT and bbs5 morphant embryos. (F) Estimation of GFR in zebrafish embryos was performed by measuring
change in cardiac luminosity of both WT and morphant embryos after cardiac sinus fluorescent dextran injection. Mean luminescence +/- SEM
(arbitrary units) is plotted versus time, up to 48 hours post injection. Morphant embryos retained significantly more fluorescent dextran at
24 hours (P = 0.005) and at 48 hours (P = 0.002). (G) At 72 hpf, compared to WT control, bbs5 morphant embryos revealed disrupted and fewer
numbers of cilia in the dilated pronephros. Scale bar 10 μm).
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discrete basal body localisation (with loss of colocalisation
with pericentrin) and an intracellular diffuse localisation
(Figure 6C,D).Discussion
BBS is a genetically heterogeneous disorder. To date,
mutations in 18 genes (BBS1-18) are known to cause the
phenotype [14,16]. Bioinformatics analysis of these genes
Figure 6 Comparison of wildtype (WT) and mutant BBS5-NT-GFP expression and localisation in HEK293 cells. Confocal fluorescent
images (overlay, plus individual fluorescent channels respectively) from WT BBS5-NT-GFP (A,B) and mutant (Mut) BBS5-NT-GFP (C,D) are shown,
together with pericentrin antibody (red) to localise centrosomes. The stain 4'-6-diamidino-2-phenylindole (DAPI) (blue) is used to stain nuclei.
(A) WT BBS5-NT-GFP colocalises with pericentrin at centrosomes. There is some diffuse cytoplasmic and intranuclear localisation of WT BBS5-NT-GFP.
(B) WT BBS5-NT-GFP colocalises with pericentrin at the centrosomes in a cell undergoing mitosis. (C,D) Mut BBS5-NT-GFP is distributed diffusely
throughout the cell and fails to colocalise with the centrosomal marker pericentrin. Scale bar 10 μm.
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genetic duplications, but are distinct genes encoding for
proteins in a linked pathway [18]. In BBS, the most com-
monly mutated genes are BBS1 and BBS10, accounting
for 23% and 21% of cases respectively [31]. BBS5 muta-
tions are rare, with only 0.4 to 2% of cases linked to a
mutation in this gene [17,31].
The intracellular role of BBS proteins has only recently
begun to be understood. A breakthrough in understand-
ing the function of BBS proteins came with the proposal
by Nachury et al. which detailed that BBS1,2,4,5,7-9
form a functional complex named the BBSome [18].
They observed that these proteins were found in stoi-
chiometric amounts after purification and identificationwith mass spectrometry, and that these proteins co-
fractionate together [18]. Interestingly, the BBSome pro-
teins are highly conserved across ciliated organisms [18].
The BBSome associates with both the ciliary membrane
and with Rab8, a GTPase which is known to promote
vesicular transport to the cell membrane [32]. BBS3 (or
ARL6), while not a BBSome protein, is also a GTPase
and thought to localise to the ciliary membrane assem-
bly point at the base of the cilium [33], and has been
shown to associate with the BBSome [34]. The BBSome
localises with intraflagellar transport (IFT) particles as it
travels the length of C. reinhardtii flagella [35] but does
not seem to be a core component of the IFT complex
[35]. Instead, it is proposed that the BBSome acts as an
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by IFT [35]. These studies come together to present the
current hypothesis that the BBSome, together with Rab8
and BBS3, function as adapters between vesicular bound
proteins and IFT proteins to promote ciliary membrane
biogenesis.
For many years, analysis of families with BBS showed
evidence of a fifth locus for the disorder at position 2q31
[1,36] but it was not until a study by Li et al. in 2004
that the BBS5 gene was discovered using an elegant
comparative genomics method [17]. They hypothesised
that unknown genes related to ciliary function will not
be present in an organism without cilia, Arabidopsis, but
present in organisms with cilia, humans and Chlamydo-
monas [17]. BBS5 is conserved and present in at least 23
orthologues including Toxoplasma gondii [18]. The mo-
lecular genetic diagnosis of patients with BBS is challen-
ging because of genetic heterogeneity of BBS. We and
others have shown that homozygosity mapping is a ro-
bust approach that is highly suited for genetically hetero-
geneous autosomal recessive disorders in populations in
which consanguinity is highly prevalent. This approach
of using genechip platforms of genome wide SNPs
helped identify a disease locus. In the family we report,
homozygosity mapping directly targeted BBS5 as the
likely cause. Phenotype-genotype correlation is typically
very poor in BBS. Although we detected a mutation in
BBS5, the phenotype we report resembles reported phe-
notypes from same population who had mutations in
BBS1, BBS3, and BBS4 [37].
In our family, the BBS5 c.966dupT (p.Ala323CysfsX57)
novel mutation led to a predicted elongation of the BBS
protein following a change in the reading frame. To
date, there are 17 previously reported mutations in
BBS5, which include missense [17,38-43], splice site mu-
tations [17,43] and small deletions/insertions [17,43,44].
However, to our knowledge a mutation that leads to a
predicted elongation of the BBS5 protein has not previ-
ously been reported. Additional studies including RT-
PCR studies and Western blotting of BBS5 protein from
affected patients would be required to confirm the pre-
dicted effect of the mutation on mRNA and protein, re-
spectively. Unfortunately this was not feasible.
In order to determine the pathogenicity of the BBS5
mutation, we used MO injection of zebrafish embryos.
The zebrafish bbs5 shares 90.9% protein identity with
human BBS5 which allows specific modelling of human
mutations. Data on a limited number (40 to 50) of bbs5
knockout zebrafish embryos have been previously re-
ported [26]. These embryos demonstrated abnormal
Kupffer’s vesicles (KV), altered heart looping and abnor-
mal melanosome transport. These findings show convin-
cing evidence that BBS5 is a ciliopathy gene with roles
in multiple developmental processes.Using mutant BBS5 mRNA to ‘rescue’ the phenotype
of bbs5 ATG MO, we saw an enhanced number of em-
bryos with a disease phenotype. In addition, the eye and
retinal phenotype remained severe. These data suggest
that the c.966dupT mutation is indeed pathogenic, al-
though the exact mechanism is not clear. A number of
possible mechanisms can be speculated. As BBS5 is part
of the BBSome, the mutation may affect other BBSome
proteins and the localisation and function of the BBSome.
The loss of the WT C-terminal amino acids may lead to
the mislocalisation of BBS5 protein and a series of C-
terminal-truncating mutations could be used to identify
such a centrosomal localisation motif.
A systematic approach to using zebrafish to evaluate
human mutations in BBS genes has previously been re-
ported [45] where a significant number of BBS-associated
mutations were suggested to have a dominant-negative
mode of action. Evidence was provided in zebrafish em-
bryos that certain mutant mRNAs produced phenotypes
significantly worse than MO alone [45]. However, it must
be remembered that when using over-expression systems,
there is the possibility of inducing an over-expression de-
fect that is not relevant to the human condition.
Using zebrafish as a model for ciliopathies is well
established, with reported models of Joubert syndrome
[21,46,47], Meckel-Gruber syndrome, [48,49] Jeune syn-
drome [50] and nephronophthisis [51-53]. There have
also been several other reported zebrafish models of BBS
[26,29,54,55] again demonstrating retinal defects, defect-
ive melanosome transport, abnormal left-right determin-
ation with defective heart looping, abnormal KVs with
defective cilia and kidney anomalies [26,29,54,55]. The
establishment of left-right asymmetry in the zebrafish is
secondary to an asymmetric fluid flow in KV, resulting
in asymmetric gene expression across the whole of the
developing embryo [56]. The abnormal cardiac looping
secondary to bbs gene knockdown shown here and by
others [26] is likely to be secondary to a cilial defect
within KV and part of a generalised laterality defect.
In bbs5 morphant zebrafish, we have demonstrated
dilatation as well as pronephric and cloacal cysts. Further-
more, in the bbs5 morphants we were able to demonstrate
a reduction in renal excretory function. In zebrafish, cilia
in the pronephros are motile and are important for driving
fluid flow within these organs. Disruption of cilia structure
or motility in the pronephros leads to fluid accumulation
and cystic dilatation [57]. In bbs5 morphants, the pro-
nephic ducts, as well being dilated, had a reduced and ir-
regular pattern of cilia.
Within the family we describe there were renal anomal-
ies in two out of the three affected siblings. Renal anomal-
ies have a reported prevalence in BBS patients of 24%,
although only 52% of patients had undergone an investi-
gative renal examination [58]. Renal anomalies may be
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calyceal clubbing, foetal lobulation, dysplastic kidneys,
unilateral agenesis, hydronephrosis and horseshoe kid-
ney implicating BBS5 in normal renal development [58].
A progressive decline in renal function in BBS patients
may also be seen and may be secondary to vesicouretic
reflux and obstruction leading to scarring. Renal disease
is a major cause of mortality in BBS patients. Reviewing
20 BBS patients, it was revealed that all patients had ei-
ther structural or functional renal abnormalities and
three had established renal failure [59]. The functional
defects included inability to concentrate urine and renal
tubular acidification defects, implicating a dysfunctional
renal collecting duct in a similar manner to nephro-
nophthisis [60]. Chronic kidney disease progressing to
established renal failure is a significant cause of morbid-
ity and mortality in patients with BBS [8]. The findings
of pronephric dilatation, together with reduced excre-
tory function in bbs5 morphants, implicate bbs5 in both
renal development and functional maintenance of the
pronephros. We speculate that these defects may be
secondary to renal ciliary dysfunction where bbs pro-
teins coordinate ciliary proteins and ciliary signalling.
Remarkably, these zebrafish morphant studies of bbs
genes demonstrate a high degree of concordance and fit
well with phenotypes reported in humans. Taken to-
gether with our data, we confirm that zebrafish are a
valid model for the study of BBS genes.
At a cellular level, genes that are mutated in ciliopa-
thies can affect ciliary signalling in different ways. This
may be through changes in cilia structure, in mistarget-
ing of signalling molecules or effecting the sensory role
of primary cilia [61]. It is known that BBS5 protein is lo-
calized to basal bodies just beneath the cilia [17]. We
confirm a basal body localisation for GFP-tagged BBS5,
which became mislocalised upon introduction of the
mutation. The (p.Ala323CysfsX57) mutation affects the
C-terminal amino acids of the BBS5 protein and does
not disrupt the PH domains of BBS5 [18]. Previously, it
has been shown that following BBS5 knockdown, centrin
and pericentrin were still targeted to centrosomes and
centriolar satellite function remained intact, however
ciliogenesis was disrupted [18]. In HEK293 cells trans-
fected with mutant BBS5, we confirm a normal expres-
sion pattern of pericentrin with complete loss of
colocalisation with BBS5. This data is comparable to the
BBS4 mutant allele L327P, which failed to colocalise with
γ-tubulin in post-mitotic cells [45].
Conclusions
In conclusion we describe a consanguineous Saudi Arabian
family with clinical features of BBS, together with a novel
mutation in BBS5. Modelling this disease in zebrafish
mimics the human disease, and pathogenicity of the novelBBS5 mutation is demonstrated by the inability of mutant
mRNA to rescue morphant zebrafish phenotype as well as
mislocalisation of mutant BBS5 protein in renal epithelial
cells.
Additional files
: Figure S1. Light and fluorescence microscopy of
renal cysts in bbs5 morphants and rescue with WT bbs5 mRNA. Left
panels show bright-field images of 72 hpf embryos and right panels
show immunofluorescence images, using claudin-Lyn-GFP embryos
which express GFP throughout the pronephros (as well as forebrain and
ear). (A,B) Uninjected fish (Control). (C-H) Morphological defects are seen
in bb5 morphant embryos. bbs5 morphant embryos show pronephros
dilatation and cyst formation which is subtle on light microscopy (black
arrows) but more easily identified under fluorescence microscopy (white
arrows). (I-N) Morphant phenotypes of tail abnormalities, pronephric duct
dilatation /cysts are (I-L) partially and (M,N) fully rescued by co-injection
with WT bbs5 mRNA.
: Figure S2. Expression of WT and mutant BBS5-NT-GFP.
Western blotting confirming protein expression of the predicted size
(arrowed) for WT and mutant BBS-NT-GFP (predicted molecular weight
45 kDa BBS5 + 27 kDa GFP = 72 kDa).
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